ANI Pharmaceuticals, Inc. v. Cabaret Biotech Ltd.

CourtDistrict Court, S.D. New York
DecidedApril 26, 2020
Docket1:19-cv-05409
StatusUnknown

This text of ANI Pharmaceuticals, Inc. v. Cabaret Biotech Ltd. (ANI Pharmaceuticals, Inc. v. Cabaret Biotech Ltd.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ANI Pharmaceuticals, Inc. v. Cabaret Biotech Ltd., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------- X ANI PHARMACEUTICALS, INC., : : Plaintiff, : ORDER GRANTING MOTION -against- : FOR JUDGMENT ON THE : PLEADINGS CABARET BIOTECH LTD., : : 19 Civ. 5409 (AKH) Defendant. : -------------------------------------------------------------- X ALVIN K. HELLERSTEIN, U.S.D.J.: This declaratory judgment action arises out of a dispute over the interpretation of several interrelated contracts–––among them, a Tripartite Agreement, an Escrow Agreement, and an Assignment Agreement, discussed infra–––that govern royalty payments owed in relation to certain patent rights. Plaintiff moves for judgment on the pleadings, see Fed. R. Civ. P. 12(c), seeking a judgment declaring, in short, that the Escrow Agreement is unenforceable insofar as it purports to alter Plaintiff’s right to payment under the Tripartite and Assignment Agreements. Defendant, in essence, seeks a declaration inverse to that sought by Plaintiff. For the reasons set forth below, Plaintiff’s motion is granted. Factual Background The relevant facts, although complicated, are not in dispute. In 2004, Cell Genesys, Inc. (“Cell Genesys”) and The Regents of the University of California (“The Regents”), entered into an Inter-Institutional Agreement (“IIA”) regarding the commercialization of certain patent rights relating to a drug designed to treat Non-Hodgkin lymphoma. See Comp., ECF No. 22, at ¶¶ 25-29; Ans. ECF No. 12, at ¶¶ 25-29; Counterclaim, ECF No. 12, at ¶¶ 20-29. Under the IIA, Cell Genesys and The Regents agreed that The Regents would be responsible for commercializing the patent rights on behalf of both parties and that The Regents would pay Cell Genesys half of the “Net Revenues” received from its commercialization of the license. See Comp. at ¶ 29; Ans. at ¶ 29; Counterclaim at ¶ 23; IIA, ECF No. 25-1, at §§ 1.3-1.5, 4.1-4.2, 5.1. In 2012, Cell Genesys’s successor, BioSante Pharmaceuticals, Inc. (“BioSante”),1 The Regents, and Dr. Zelig Eshhar executed a three-way agreement (the “Tripartite Agreement”)

governing shared rights to (a) the patents underlying the IIA, and (b) similar patent rights held by Dr. Eshhar.2 See Comp. at ¶¶ 33-34; Counterclaim at ¶ 24; Tripartite Agmt., ECF No. 1-1. The parties to the Tripartite Agreement agreed to grant Dr. Eshhar responsibility for commercializing and licensing the patent rights on behalf of all three signatories. See Tripartite Agmt. at §§ 3.1- 3.7. As to “Financial Terms,” the Tripartite Agreement requires Dr. Eshhar to periodically pay to The Regents 25% of “Net Revenues,”3 of which amount The Regents would retain half and pay half to BioSante: 4.1. On or before April 30 of each year, Eshhar shall distribute to The Regents one-quarter (1/4) of Net Revenues accrued during the most recently completed fiscal years (which ends December 31).

4.2. The Regents shall distribute its share of the Net Revenues to BioSante as per the terms of the IIA[(half of the amount paid to the Regents)]. Each party is solely responsible for calculating and distributing to its respective inventors any share of Net Revenues due in accordance with its respective patent policy.

Id. at §§ 4.1-4.2. In the years following, Eshhar’s company, Defendant Cabaret Biotech, Ltd. (“Cabaret”) succeeded to his rights and obligations under the Tripartite Agreement, and Plaintiff ANI Pharmaceuticals, Inc. (“ANI”) succeeded, by merger, to the rights of BioSante. See Comp.

1 Cell Genesys merged with BioSante in 2009, at which time BioSante assumed all of Cell Genesys’s rights under the IIA. See Comp. at ¶ 32; Counterclaim at ¶ 23.

2 Dr. Eshhar obtained patents covering material similar to that which was covered by the patents held by Cell Genesys and The Regents. See Comp. at ¶ 30-33; Ans., ECF No. 12, at ¶¶ 30-33; Counterclaim at ¶¶ 20-22.

3 “Net revenues” are defined as “proceeds received by Eshhar from milestone payments, royalty and sublicense fees obtained from the licensing of Patent Rights less all reasonable and actual out-of-pocket costs … incurred by [The Regents] or Eshhar in the preparation, filing, prosecution, and licensing of Patent Rights.” Tripartite Agmt. at § 1.3. at ¶¶ 43-44; Ans. at ¶¶ 43-44; Counterclaim at ¶ 33. Thus, Cabaret had the obligation to pay a portion of Net Revenues to The Regents, and The Regents had the obligation to pay half of the amount it received to ANI–––all as spelled out in the Tripartite Agreement In 2013, Cabaret entered into a licensing agreement (the “License Agreement”)

with Kite Pharma, Inc. (“Kite”), under which Kite agreed to make annual payments to Cabaret, tied to the success of the commercialization of the underlying patents. Under to The Tripartite Agreement, as described above, Cabaret was required to pay a portion of the payments received from Kite to The Regents, and The Regents was then required to pass along half of that payment to ANI. Cabaret, pursuant to other agreements not relevant to the instant dispute, was required to pay portions of the payments it received from Kite to various other stakeholders. See Comp. at ¶ 57; Counterclaim at ¶ 37. In 2017, Kite was acquired by Gilead Sciences, Inc. (“Gilead”). The record is unclear as to whether Gilead assumed Kite’s obligations under the License Agreement by way of the acquisition. See Comp. at ¶¶ 6, 61-63; Counterclaim at ¶¶ 36-38. Fees and royalties were paid without major incident until October 2018, at which

time Gilead informed Cabaret, in substance, that Gilead doubted the enforceability of the patent rights held by Cabaret, and that Kite would therefore make all ensuing payments “under protest.” See Comp. at ¶ 62; Counterclaim ¶ 38. Cabaret, fearing an attempt by Gilead or Kite to “claw back” payments, sought, in Cabaret’s words, to “put in place arrangements that would allow it to pay all stakeholders pursuant to their agreements while confirming that Cabaret could recoup those funds if Gilead succeeded in clawing back payments made under protest.” Cabaret Opp. Br., ECF No. 26, at 6. To that end, Cabaret proposed to various stakeholders with an interest in the Kite payments, including ANI and The Regents, that they enter into agreements with Cabaret under which Cabaret would, among other things, withhold Kite’s payments until Cabaret could be sure it was “fully protected” against litigation with Gilead, Counterclaim at ¶¶ 45-47; Comp. at ¶¶ 64-78; Counterclaim at ¶ 47. ANI did not agree to enter any such agreement, and reminded Cabaret of ANI’s right to half of the revenues Cabaret released to The Regents. See Comp. at ¶ 69; Counterclaim at ¶¶ 46-58. Ultimately, all stakeholders, but for ANI, agreed to some form

of the arrangement proposed by Cabaret. See Counterclaim at ¶¶ 59-62. Thus, in March 2019, The Regents and Cabaret entered into a Common Interest and Escrow Agreement (the “Escrow Agreement”), which provided that Cabaret would place the payments owed to The Regents under the Tripartite Agreement into an escrow account until Gilead/Kite withdrew its protest to making payments under the License Agreement. See Comp. at ¶¶ 86-88; Counterclaim at ¶ 64; Escrow Agmt., ECF No. 1-5, at § 6. The Escrow Agreement provides in relevant part that Cabaret shall establish a new account … with a recognized financial or escrow institution and, with respect to each Payment Under Protest received by Cabaret, deposit into such account an amount equal to the distribution that [The Regents] is entitled to receive from such Payment Under Protest pursuant to the [Tripartite Agreement], all such amounts to be held in escrow for the benefit of [The Regents] …

Escrow Agmt.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Farmland Irrigation Co. v. Dopplmaier
308 P.2d 732 (California Supreme Court, 1957)
Riverside Rancho Corp. v. Cowan
198 P.2d 526 (California Court of Appeal, 1948)
Hotle v. Miller
334 P.2d 849 (California Supreme Court, 1959)
Hayden v. Paterson
594 F.3d 150 (Second Circuit, 2010)
L-7 Designs, Inc. v. Old Navy, LLC
647 F.3d 419 (Second Circuit, 2011)
Zalkind v. Ceradyne, Inc.
194 Cal. App. 4th 1010 (California Court of Appeal, 2011)
Cit Bank, N.A. v. Neris
385 F. Supp. 3d 241 (S.D. Illinois, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
ANI Pharmaceuticals, Inc. v. Cabaret Biotech Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ani-pharmaceuticals-inc-v-cabaret-biotech-ltd-nysd-2020.